Research
Neural
Tirzepatide is associated with a lower risk of dementia versus semaglutide (HR 0.69, 95% CI 0.48-0.99, p = 0.04).
Practitioners may consider tirzepatide as a potentially safer option for reducing dementia risk in patients with type 2 diabetes.
StrongSupportsmedium confidence
Tirzepatide was associated with a lower risk of dementia versus semaglutide (HR 0.69, 95% CI 0.48-0.99, p = 0.04).
Why this rating
Based on the large cohort study design.
Source
Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study
Alhena Younis et al. · Diabetes Research and Clinical Practice · 2026
cohort · n=14462
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →